Should persons with acute myeloid leukemia have a transplant in first remission?

[1]  R. Gale,et al.  What does MRD in leukemia really mean? , 2014, Leukemia.

[2]  M. Labopin,et al.  A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality , 2014, Bone Marrow Transplantation.

[3]  Cynthia D Mulrow,et al.  Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change , 2014, Annals of Internal Medicine.

[4]  D. Marin.  Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Bob Löwenberg,et al.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Scott,et al.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  James M Robins,et al.  Randomized Trials Analyzed as Observational Studies , 2013, Annals of Internal Medicine.

[8]  L. Bullinger,et al.  The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. , 2013, Blood.

[9]  R. Gale,et al.  Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors , 2013, Acta Haematologica.

[10]  R. Hills,et al.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Rowe,et al.  The myth of the second remission of acute leukemia in the adult. , 2013, Blood.

[12]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[13]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[14]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Labopin,et al.  A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study , 2011, Leukemia.

[16]  R. Gale,et al.  SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS , 2011, Bone Marrow Transplantation.

[17]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[18]  F. Ciceri,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia , 2010, Haematologica.

[19]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. , 2009, Blood.

[20]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[21]  R. Gale,et al.  Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? , 2009, Bone Marrow Transplantation.

[22]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[23]  R. Hills,et al.  No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. , 2005, Blood.

[24]  C. Bloomfield,et al.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Gale,et al.  Modeling minimal residual disease (MRD)-testing. , 2003, Leukemia research.

[28]  G. Hortobagyi,et al.  Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer , 2000, Clinical transplantation.

[29]  M. Pencina,et al.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.

[30]  R. Gale,et al.  Erratum: Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? (Bone Marrow Transplantation (2009) vol. 43 (435-446) 10.1038/bmt.2008.447) , 2009 .